Empagliflozin as a potential therapy for PCOS: Restoring hormonal balance and ovarian function in a letrozole-induced rat model
Abstract
BACKGROUND
Polycystic ovarian syndrome (PCOS) is a prevalent endocrine disorder that often leads to infertility. The characteristic hyperandrogenemia and elevated luteinizing hormone /follicle stimulating hormone ratio, resulting in ovulation failure, are the hallmarks of PCOS. Recent preclinical and clinical studies revealed the potential of empagliflozin (EMPA; a sodium-glucose cotransporter-2 inhibitor) to improve PCOS symptoms. However, the effects of EMPA on endocrine disturbances and ovarian cyst formation were not thoroughly investigated.
OBJECTIVES
The primary objective of this study was to explore the potential of EMPA as a treatment for PCOS.
METHODS
PCOS was induced by daily administration of letrozole (1 mg/kg for 21 days). The PCOS group was then divided into PCOS (untreated), PCOS+EMPA (10 mg/kg), and PCOS + metformin (300 mg/kg). All groups, except for the vehicle-treated group, continued to receive letrozole throughout the 21-day treatment period. Serum and ovaries were collected for various measurements at the end of the experiments.
RESULTS
The results of the study showed that induction of PCOS resulted in high testosterone levels, luteinizing hormone /follicle stimulating hormone ratio, and ovarian weights. Disturbed apoptosis and high transforming growth factor-β and inducible nitric oxide synthase expression were also evident in the PCOS group. EMPA treatment resulted in an ameliorative effect of these changes, comparable to metformin's effect.…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.